Improved therapy of non-Hodgkin's lymphoma xenografts using radionuclides pretargeted with a new anti-CD20 bispecific antibody
暂无分享,去创建一个
W. Mcbride | D. Goldenberg | R. Sharkey | I. Horak | C. Chang | H. Karacay | Goldenberg Dm | Chien‐Hsing Chang | C. Chang | McBride Wj
[1] R. Tsang,et al. Hodgkin’s lymphoma , 2018, Concise Notes in Oncology for MRCP and MRCS.
[2] W. Mcbride,et al. Improving the Delivery of Radionuclides for Imaging and Therapy of Cancer Using Pretargeting Methods , 2005, Clinical Cancer Research.
[3] J. Vose,et al. Phase 1 trial of a novel anti-CD20 fusion protein in pretargeted radioimmunotherapy for B-cell non-Hodgkin lymphoma. , 2004, Blood.
[4] L. Gordon,et al. Durable responses after ibritumomab tiuxetan radioimmunotherapy for CD20+ B-cell lymphoma: long-term follow-up of a phase 1/2 study. , 2004, Blood.
[5] D. Goldenberg,et al. Characterization of a New Humanized Anti-CD20 Monoclonal Antibody, IMMU-106, and Its Use in Combination with the Humanized Anti-CD22 Antibody, Epratuzumab, for the Therapy of Non-Hodgkin’s Lymphoma , 2004, Clinical Cancer Research.
[6] J. Vose. Bexxar: novel radioimmunotherapy for the treatment of low-grade and transformed low-grade non-Hodgkin's lymphoma. , 2004, The oncologist.
[7] W. Mcbride,et al. Optimizing bispecific antibody pretargeting for use in radioimmunotherapy. , 2003, Clinical cancer research : an official journal of the American Association for Cancer Research.
[8] W. McBride,et al. Development of new multivalent-bispecific agents for pretargeting tumor localization and therapy. , 2003, Clinical cancer research : an official journal of the American Association for Cancer Research.
[9] W. Oyen,et al. Pretargeted radioimmunotherapy of cancer: progress step by step. , 2003, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.
[10] W. McBride,et al. Radioimmunotherapy: Is avidin-biotin pretargeting the preferred choice among pretargeting methods? , 2003, European Journal of Nuclear Medicine and Molecular Imaging.
[11] Gary L Griffiths,et al. A universal pretargeting system for cancer detection and therapy using bispecific antibody. , 2003, Cancer research.
[12] L. Gordon,et al. Randomized controlled trial of yttrium-90-labeled ibritumomab tiuxetan radioimmunotherapy versus rituximab immunotherapy for patients with relapsed or refractory low-grade, follicular, or transformed B-cell non-Hodgkin's lymphoma. , 2002, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[13] Damon L. Meyer,et al. A comparative evaluation of conventional and pretargeted radioimmunotherapy of CD20-expressing lymphoma xenografts. , 2001, Blood.
[14] P. Weiden,et al. Pretargeted radioimmunotherapy (PRIT) for treatment of non-Hodgkin's lymphoma (NHL). , 2001, Critical reviews in oncology/hematology.
[15] J. Vose,et al. Pivotal study of iodine I 131 tositumomab for chemotherapy-refractory low-grade or transformed low-grade B-cell non-Hodgkin's lymphomas. , 2001, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[16] E. Gautherot,et al. In vitro and in vivo targeting of radiolabeled monovalent and divalent haptens with dual specificity monoclonal antibody conjugates: enhanced divalent hapten affinity for cell-bound antibody conjugate. , 1989, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.
[17] J. Vose,et al. Phase 1 trial of a novel anti-CD 20 fusion protein in pretargeted radioimmunotherapy for B-cell non-Hodgkin lymphoma , 2004 .
[18] G. Griffiths,et al. 90Y-DOTA-hLL2: an agent for radioimmunotherapy of non-Hodgkin's lymphoma. , 2003, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.